공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

항비만제 시장 조사 보고서 예측(-2025년) : COVID-19의 누적 영향

Anti-Obesity Drugs Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2021년 06월 상품 코드 1002739
페이지 정보 영문 191 Pages
가격
US $ 3,949 ₩ 4,523,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 5,669,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 6,814,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 9,105,000 PDF (Site License) + Excel
US $ 9,949 ₩ 11,396,000 PDF (Enterprise License) + Excel


항비만제 시장 조사 보고서 예측(-2025년) : COVID-19의 누적 영향 Anti-Obesity Drugs Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19
발행일 : 2021년 06월 페이지 정보 : 영문 191 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 항비만제 시장 규모는 2020년 31억 7,357만 달러에서 2025년 말까지 42억 1,356만 달러에 달할 것으로 예측됩니다.

COVID-19는 미증유의 세계적인 공중위생상 긴급사태이며, 모든 업계에 영향을 미쳐 왔습니다. 이 장기적 영향은 예측기간 중 업계의 성장에 영향을 미칠 것으로 예측됩니다. 우리가 진행하고 있는 조사에서는 기저에 있는 COVID-19의 문제와 향후 방향을 확실히 다루기 위해 조사 범위를 확대시키고 있습니다. 소비자의 행동과 수요 변화, 구입 패턴, 공급망 재설정, 현재 시장 동향 및 정부의 중요한 개입 등을 고려하면서, COVID-19에 대한 인사이트를 제공합니다. 업데이트된 조사에서는 COVID-19가 시장에 미치는 영향을 고려하고, 인사이트, 분석, 예측 등을 제공합니다.

세계의 항비만제(Anti-Obesity Drugs) 시장에 대해 조사했으며, 시장 개요, 지역별 동향, COVID-19의 누적 영향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

  • 조사 목적
  • 시장 세분화와 범위
  • 조사 대상년도
  • 통화와 가격
  • 언어
  • 제한 사항
  • 이해관계자

제2장 조사 방법

  • 조사 프로세스
    • 정의 : 조사 목적
    • 결정 : 조사 설계
    • 준비 : 조사 툴
    • 수집 : 데이터 소스
    • 분석 : 데이터 분석
    • 책정 : 데이터 검증
    • 공개 : 조사 보고서
    • 반복 : 보고서 업데이트
  • 조사 시행
    • 개시 : 조사 프로세스
    • 계획 : 조사 계획 작성
    • 시행 : 조사 시행
    • 검증 : 발견 및 분석
    • 출판물 : 조사 보고
  • 조사 성과

제3장 개요

  • 서론
  • 시장 전망
  • 유형별 전망
  • 지역별 전망
  • 경쟁사별 전망

제4장 시장 개요

  • 서론
  • COVID-19의 누적 영향

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • Porter의 산업 분석
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 고객의 교섭력
    • 공급 기업의 교섭력
    • 업계 경쟁

제6장 아메리카의 항비만제 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제7장 아시아태평양의 항비만제 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 한국
  • 태국

제8장 유럽, 중동 및 아프리카의 항비만제 시장

  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트(UAE)
  • 영국

제9장 경쟁 구도

  • FPNV 포지셔닝 매트릭스
    • Quadrants
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 시장 점유율 분석
  • 경쟁사의 SWOT 분석
  • 경쟁 시나리오
    • 인수합병(M&A)
    • 계약/협업/제휴
    • 신제품 발매와 강화
    • 투자 및 펀딩
    • 수상/표창/확대

제10장 기업 개요

  • Alizyme
  • Arena Pharmaceuticals Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Orexigen Therapeutics
  • Pfizer Inc.
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceuticals
  • Vivus Inc.
  • Zafgan
  • Zydus Cadila

제11장 부록

  • 디스커션 가이드
  • 라이선스와 가격
LSH 21.05.14

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 5. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 6. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 7. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 8. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 9. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 10. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 11. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 13. CALIFORNIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 14. FLORIDA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 15. ILLINOIS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 16. NEW YORK ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 17. OHIO ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 18. PENNSYLVANIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. TEXAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 23. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 34. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL ANTI-OBESITY DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 46. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 47. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET: SCORES
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET: RANKING
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET: LICENSE & PRICING
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET: CONTACT DETAILS

The Global Anti-Obesity Drugs Market size was estimated at USD 3,173.57 Million in 2020 and expected to reach USD 3,374.55 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.67% to reach USD 4,675.53 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anti-Obesity Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Geography, the Anti-Obesity Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Obesity Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Obesity Drugs Market, including Alizyme, Arena Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Orexigen Therapeutics, Pfizer Inc., Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceuticals, Vivus Inc., Zafgan, and Zydus Cadila.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anti-Obesity Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Obesity Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Obesity Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anti-Obesity Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anti-Obesity Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Anti-Obesity Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anti-Obesity Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Geography Outlook
  • 3.4. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of obesity and related chronic diseases
      • 5.1.1.2. Adoption of sedentary lifestyles
      • 5.1.1.3. Rising consumption of unhealthy fast-foods and ready meals
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing inclination towards health & fitness
      • 5.1.3.2. Rising awareness among people with collaborative strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options in market
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Americas Anti-Obesity Drugs Market

  • 6.1. Introduction
  • 6.2. Argentina
  • 6.3. Brazil
  • 6.4. Canada
  • 6.5. Mexico
  • 6.6. United States
    • 6.6.1. California
    • 6.6.2. Florida
    • 6.6.3. Illinois
    • 6.6.4. New York
    • 6.6.5. Ohio
    • 6.6.6. Pennsylvania
    • 6.6.7. Texas

7. Asia-Pacific Anti-Obesity Drugs Market

  • 7.1. Introduction
  • 7.2. China
  • 7.3. India
  • 7.4. Indonesia
  • 7.5. Japan
  • 7.6. Malaysia
  • 7.7. Philippines
  • 7.8. South Korea
  • 7.9. Thailand

8. Europe, Middle East & Africa Anti-Obesity Drugs Market

  • 8.1. Introduction
  • 8.2. France
  • 8.3. Germany
  • 8.4. Italy
  • 8.5. Netherlands
  • 8.6. Qatar
  • 8.7. Russia
  • 8.8. Saudi Arabia
  • 8.9. South Africa
  • 8.10. Spain
  • 8.11. United Arab Emirates
  • 8.12. United Kingdom

9. Competitive Landscape

  • 9.1. FPNV Positioning Matrix
    • 9.1.1. Quadrants
    • 9.1.2. Business Strategy
    • 9.1.3. Product Satisfaction
  • 9.2. Market Ranking Analysis
  • 9.3. Market Share Analysis, By Quadrant
  • 9.4. Market Share Analysis, By Company
  • 9.5. Competitive Scenario
    • 9.5.1. Merger & Acquisition
    • 9.5.2. Agreement, Collaboration, & Partnership
    • 9.5.3. New Product Launch & Enhancement
    • 9.5.4. Investment & Funding
    • 9.5.5. Award, Recognition, & Expansion

10. Company Usability Profiles

  • 10.1. Alizyme
  • 10.2. Arena Pharmaceuticals Inc.
  • 10.3. Bayer AG
  • 10.4. Boehringer Ingelheim GmbH
  • 10.5. Bristol-Myers Squibb
  • 10.6. Currax Pharmaceuticals LLC
  • 10.7. Eisai Co. Ltd
  • 10.8. F. Hoffmann-La Roche AG
  • 10.9. GlaxoSmithKline PLC
  • 10.10. Merck & Co. Inc.
  • 10.11. Norgine BV
  • 10.12. Novo Nordisk AS
  • 10.13. Orexigen Therapeutics
  • 10.14. Pfizer Inc.
  • 10.15. Rhythm Pharmaceuticals
  • 10.16. Shionogi USA
  • 10.17. Takeda Pharmaceuticals
  • 10.18. Vivus Inc.
  • 10.19. Zafgan
  • 10.20. Zydus Cadila

11. Appendix

  • 11.1. Discussion Guide
  • 11.2. License & Pricing
  • 11.3. Contact Details
Back to Top
전화 문의
F A Q